Strategies to manage hepatitis C virus (HCV) disease burden

H Wedemeyer; A S Duberg; M Buti; W M Rosenberg; S Frankova; G Esmat; N Örmeci; H Van Vlierberghe; M Gschwantler; U Akarca; S Aleman; I Balık; T Berg; F Bihl; M Bilodeau; A J Blasco; C E Brandão Mello; P Bruggmann; F Calinas; J L Calleja; H Cheinquer; P B Christensen; M Clausen; H S M Coelho; M Cornberg; M E Cramp; G J Dore; W Doss; M H El-Sayed; G Ergör; C Estes; K Falconer; J Félix; M L G Ferraz; P R Ferreira; J García-Samaniego; J Gerstoft; J A Giria; F L Gonçales; M Guimarães Pessôa; C Hézode; S J Hindman; H Hofer; P Husa; R Idilman; M Kåberg; K D E Kaita; A Kautz; S Kaymakoglu; M Krajden; H Krarup; W Laleman; D Lavanchy; P Lázaro; R T Marinho; P Marotta; S Mauss; M C Mendes Correa; C Moreno; B Müllhaupt; R P Myers; V Nemecek; A L H Øvrehus; J Parkes; K M Peltekian; A Ramji; H Razavi; N Reis; S K Roberts; F Roudot-Thoraval; S D Ryder; R Sarmento-Castro; C Sarrazin; D Semela; M Sherman; G E Shiha; J Sperl; P Stärkel; R E Stauber; A J Thompson; P Urbanek; P Van Damme; I van Thiel; D Vandijck; W Vogel; I Waked; N Weis; J Wiegand; A Yosry; A Zekry; F Negro; W Sievert; E Gower

doi:10.1111/jvh.12249

Strategies to manage hepatitis C virus (HCV) disease burden

H Wedemeyer, A S Duberg, M Buti, W M Rosenberg, S Frankova, G Esmat, N Örmeci, H Van Vlierberghe, M Gschwantler, U Akarca, S Aleman, I Balık, T Berg, F Bihl, M Bilodeau, A J Blasco, C E Brandão Mello, P Bruggmann, F Calinas, J L CallejaH Cheinquer, P B Christensen, M Clausen, H S M Coelho, M Cornberg, M E Cramp, G J Dore, W Doss, M H El-Sayed, G Ergör, C Estes, K Falconer, J Félix, M L G Ferraz, P R Ferreira, J García-Samaniego, J Gerstoft, J A Giria, F L Gonçales, M Guimarães Pessôa, C Hézode, S J Hindman, H Hofer, P Husa, R Idilman, M Kåberg, K D E Kaita, A Kautz, S Kaymakoglu, M Krajden, H Krarup, W Laleman, D Lavanchy, P Lázaro, R T Marinho, P Marotta, S Mauss, M C Mendes Correa, C Moreno, B Müllhaupt, R P Myers, V Nemecek, A L H Øvrehus, J Parkes, K M Peltekian, A Ramji, H Razavi, N Reis, S K Roberts, F Roudot-Thoraval, S D Ryder, R Sarmento-Castro, C Sarrazin, D Semela, M Sherman, G E Shiha, J Sperl, P Stärkel, R E Stauber, A J Thompson, P Urbanek, P Van Damme, I van Thiel, D Vandijck, W Vogel, I Waked, N Weis, J Wiegand, A Yosry, A Zekry, F Negro, W Sievert, E Gower

Department of Clinical Medicine

158 Citations (Scopus)

Abstract

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

Original language	English
Journal	Journal of Viral Hepatitis
Volume	21
Issue number	s1
Pages (from-to)	60-89
Number of pages	30
ISSN	1352-0504
DOIs	https://doi.org/10.1111/jvh.12249
Publication status	Published - 1 May 2014

Keywords

Adolescent
Adult
Aged
Aged, 80 and over
Antiviral Agents
Diagnostic Tests, Routine
Disease Eradication
Drug Therapy, Combination
Female
Global Health
Hepatitis C, Chronic
Humans
Incidence
Male
Middle Aged
Models, Statistical
Prevalence
Young Adult

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jvh.12249

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jvh.12249

Cite this

Wedemeyer, H., Duberg, A. S., Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Örmeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U., Aleman, S., Balık, I., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Calinas, F., ... Gower, E. (2014). Strategies to manage hepatitis C virus (HCV) disease burden. Journal of Viral Hepatitis, 21 (s1), 60-89. https://doi.org/10.1111/jvh.12249

Wedemeyer, H, Duberg, AS, Buti, M, Rosenberg, WM, Frankova, S, Esmat, G, Örmeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, El-Sayed, MH, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Guimarães Pessôa, M, Hézode, C, Hindman, SJ, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, RT, Marotta, P, Mauss, S, Mendes Correa, MC, Moreno, C, Müllhaupt, B, Myers, RP, Nemecek, V, Øvrehus, ALH, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, GE, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Vandijck, D, Vogel, W, Waked, I, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W & Gower, E 2014, 'Strategies to manage hepatitis C virus (HCV) disease burden', Journal of Viral Hepatitis, vol. 21 , no. s1, pp. 60-89. https://doi.org/10.1111/jvh.12249

@article{3ba1ce1ea76d4c8ea82f1925a95242e1,

title = "Strategies to manage hepatitis C virus (HCV) disease burden",

abstract = "The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.",

keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents, Diagnostic Tests, Routine, Disease Eradication, Drug Therapy, Combination, Female, Global Health, Hepatitis C, Chronic, Humans, Incidence, Male, Middle Aged, Models, Statistical, Prevalence, Young Adult",

author = "H Wedemeyer and Duberg, {A S} and M Buti and Rosenberg, {W M} and S Frankova and G Esmat and N {\"O}rmeci and {Van Vlierberghe}, H and M Gschwantler and U Akarca and S Aleman and I Balık and T Berg and F Bihl and M Bilodeau and Blasco, {A J} and {Brand{\~a}o Mello}, {C E} and P Bruggmann and F Calinas and Calleja, {J L} and H Cheinquer and Christensen, {P B} and M Clausen and Coelho, {H S M} and M Cornberg and Cramp, {M E} and Dore, {G J} and W Doss and El-Sayed, {M H} and G Erg{\"o}r and C Estes and K Falconer and J F{\'e}lix and Ferraz, {M L G} and Ferreira, {P R} and J Garc{\'i}a-Samaniego and J Gerstoft and Giria, {J A} and Gon{\c c}ales, {F L} and {Guimar{\~a}es Pess{\^o}a}, M and C H{\'e}zode and Hindman, {S J} and H Hofer and P Husa and R Idilman and M K{\aa}berg and Kaita, {K D E} and A Kautz and S Kaymakoglu and M Krajden and H Krarup and W Laleman and D Lavanchy and P L{\'a}zaro and Marinho, {R T} and P Marotta and S Mauss and {Mendes Correa}, {M C} and C Moreno and B M{\"u}llhaupt and Myers, {R P} and V Nemecek and {\O}vrehus, {A L H} and J Parkes and Peltekian, {K M} and A Ramji and H Razavi and N Reis and Roberts, {S K} and F Roudot-Thoraval and Ryder, {S D} and R Sarmento-Castro and C Sarrazin and D Semela and M Sherman and Shiha, {G E} and J Sperl and P St{\"a}rkel and Stauber, {R E} and Thompson, {A J} and P Urbanek and {Van Damme}, P and {van Thiel}, I and D Vandijck and W Vogel and I Waked and N Weis and J Wiegand and A Yosry and A Zekry and F Negro and W Sievert and E Gower",

note = "{\textcopyright} 2014 John Wiley & Sons Ltd.",

year = "2014",

month = may,

day = "1",

doi = "10.1111/jvh.12249",

language = "English",

volume = "21 ",

pages = "60--89",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell",

number = "s1",

}

TY - JOUR

T1 - Strategies to manage hepatitis C virus (HCV) disease burden

AU - Wedemeyer, H

AU - Duberg, A S

AU - Buti, M

AU - Rosenberg, W M

AU - Frankova, S

AU - Esmat, G

AU - Örmeci, N

AU - Van Vlierberghe, H

AU - Gschwantler, M

AU - Akarca, U

AU - Aleman, S

AU - Balık, I

AU - Berg, T

AU - Bihl, F

AU - Bilodeau, M

AU - Blasco, A J

AU - Brandão Mello, C E

AU - Bruggmann, P

AU - Calinas, F

AU - Calleja, J L

AU - Cheinquer, H

AU - Christensen, P B

AU - Clausen, M

AU - Coelho, H S M

AU - Cornberg, M

AU - Cramp, M E

AU - Dore, G J

AU - Doss, W

AU - El-Sayed, M H

AU - Ergör, G

AU - Estes, C

AU - Falconer, K

AU - Félix, J

AU - Ferraz, M L G

AU - Ferreira, P R

AU - García-Samaniego, J

AU - Gerstoft, J

AU - Giria, J A

AU - Gonçales, F L

AU - Guimarães Pessôa, M

AU - Hézode, C

AU - Hindman, S J

AU - Hofer, H

AU - Husa, P

AU - Idilman, R

AU - Kåberg, M

AU - Kaita, K D E

AU - Kautz, A

AU - Kaymakoglu, S

AU - Krajden, M

AU - Krarup, H

AU - Laleman, W

AU - Lavanchy, D

AU - Lázaro, P

AU - Marinho, R T

AU - Marotta, P

AU - Mauss, S

AU - Mendes Correa, M C

AU - Moreno, C

AU - Müllhaupt, B

AU - Myers, R P

AU - Nemecek, V

AU - Øvrehus, A L H

AU - Parkes, J

AU - Peltekian, K M

AU - Ramji, A

AU - Razavi, H

AU - Reis, N

AU - Roberts, S K

AU - Roudot-Thoraval, F

AU - Ryder, S D

AU - Sarmento-Castro, R

AU - Sarrazin, C

AU - Semela, D

AU - Sherman, M

AU - Shiha, G E

AU - Sperl, J

AU - Stärkel, P

AU - Stauber, R E

AU - Thompson, A J

AU - Urbanek, P

AU - Van Damme, P

AU - van Thiel, I

AU - Vandijck, D

AU - Vogel, W

AU - Waked, I

AU - Weis, N

AU - Wiegand, J

AU - Yosry, A

AU - Zekry, A

AU - Negro, F

AU - Sievert, W

AU - Gower, E

PY - 2014/5/1

Y1 - 2014/5/1

N2 - The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

AB - The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antiviral Agents

KW - Diagnostic Tests, Routine

KW - Disease Eradication

KW - Drug Therapy, Combination

KW - Female

KW - Global Health

KW - Hepatitis C, Chronic

KW - Humans

KW - Incidence

KW - Male

KW - Middle Aged

KW - Models, Statistical

KW - Prevalence

KW - Young Adult

U2 - 10.1111/jvh.12249

DO - 10.1111/jvh.12249

M3 - Journal article

C2 - 24713006

SN - 1352-0504

VL - 21

SP - 60

EP - 89

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

IS - s1

ER -

Strategies to manage hepatitis C virus (HCV) disease burden

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this